Assessment of Factors Associated with Unfavorable Outcomes among Drug-Resistant TB Patients: A 6-Year Retrospective Study from Pakistan

The spread of drug-resistant tuberculosis (DR TB) poses significant challenges to the control and successful eradication of TB globally. The current retrospective study was designed to evaluate the treatment outcomes and identify the risk factors associated with unsuccessful outcomes among DR TB patients. A total of 277/308 eligible DR TB patients were enrolled for treatment at the programmatic management unit of DR TB at the Pakistan Institute of Medical Sciences, Islamabad between January 2014 and July 2019. Treatment outcomes were defined according to the WHO recommendations. Death, treatment failure, and lost to follow-up (LTFU) were collectively grouped as unsuccessful treatment outcomes, whereas cured and treatment completed were summed up together as successful treatment outcomes. Out of the total 277 patients, 265 (95.67%) were multidrug/rifampicin-resistant TB (MDR/RR-TB) cases, 8 (2.89%) were isoniazid resistant cases, and 4 (1.44%) were extensively drug-resistant ones. In the current cohort, a total of 177 (63.9%) achieved successful treatment outcomes. Among them, 153 (55.2%) were declared cured and 24 (8.7%) completed their treatment. Of the remaining 100 (36.1%) patients with unsuccessful outcomes, 60 (21.7%) died, 32 (11.5%) were LTFU, and 8 (2.9%) had failed treatment. The proportion of male patients was relatively higher (55.2%), within the age group of 21–40 years (47.3%) and lived in rural areas (66.8%). The multivariate analysis revealed that unsuccessful outcomes had a statistically significant association with being male (adjusted odds ratio, AOR: 1.92, 95% confidence interval (CI): 1.10–3.36), being in an age group above 60 years (AOR: 3.34, 95% CI: 1.09–10.1), suffering from any comorbidity (AOR: 2.69, 95% CI: 1.35–5.38), and the history of use of second-line drugs (AOR; 3.51, 95% CI 1.35–9.12). In conclusion, treatment outcomes among DR TB patients at the study site were poor and did not achieve the treatment success target (≥75%) set by the World Health Organization.

[1]  Wildo Navegantes de Araújo,et al.  Brazilian cohort study of risk factors associated with unsuccessful outcomes of drug resistant tuberculosis , 2021, BMC Infectious Diseases.

[2]  Z. El-Khatib,et al.  Tuberculosis Treatment Outcome and Predictors in Africa: A Systematic Review and Meta-Analysis , 2021, International journal of environmental research and public health.

[3]  Jie Chang,et al.  Impact of Protracted Displacement on Delay in the Diagnosis Associated with Treatment Outcomes: A Cross-Sectional Study in Internally Displaced Tuberculosis Patients of Pakistan , 2021, International journal of environmental research and public health.

[4]  M. Mansournia,et al.  National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: a 10-year retrospective cohort study , 2021, BMJ Open.

[5]  F. Osei,et al.  Treatment Outcomes and Associated Factors in Tuberculosis Patients at Atwima Nwabiagya District, Ashanti Region, Ghana: A Ten-Year Retrospective Study , 2021, Tuberculosis research and treatment.

[6]  E. Netto,et al.  Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013–2015: A retrospective cohort study , 2021, PloS one.

[7]  Jie Chang,et al.  A Simulated Client Exploration of Nonprescription Dispensing of Antibiotics at Drugstores for Pediatric Acute Diarrhea and Upper Respiratory Infection in Lahore, Pakistan , 2021, Infection and drug resistance.

[8]  H. Gesesew,et al.  Predictors of lost to follow up from antiretroviral therapy among adults in sub-Saharan Africa: a systematic review and meta-analysis , 2021, Infectious Diseases of Poverty.

[9]  J. Nachega,et al.  Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts , 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[10]  H. Bazyar,et al.  Bedaquiline: current status and future perspectives. , 2021, Journal of global antimicrobial resistance.

[11]  M. Nabwana,et al.  Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study , 2021, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.

[12]  Teshager Worku,et al.  Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in Ethiopia: A Systematic Review and Meta-analysis. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[13]  N. Ahmad,et al.  Treatment outcomes among multidrug-resistant TB patients in Bahawal Victoria Hospital, Bahawalpur, Pakistan: a retrospective record review. , 2020, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[14]  Julie F Pallant,et al.  SPSS Survival Manual: A Step by Step Guide to Data Analysis Using IBM SPSS , 2020 .

[15]  E. Netto,et al.  Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis , 2019, PloS one.

[16]  B. Godman,et al.  Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications , 2019, Expert review of anti-infective therapy.

[17]  Shiying Li,et al.  Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis , 2019, BMC Microbiology.

[18]  A. Jaber,et al.  Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance , 2019, BMC Infectious Diseases.

[19]  S. Ahid,et al.  Treatment outcomes of drug resistant tuberculosis patients in Morocco: multi-centric prospective study , 2019, BMC Infectious Diseases.

[20]  S. van den Hof,et al.  Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan. , 2019, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[21]  E. Steyerberg.  Applications of Prediction Models , 2019, Statistics for Biology and Health.

[22]  Abrham Belachew Muluye,et al.  Poor treatment outcomes and its determinants among tuberculosis patients in selected health facilities in East Wollega, Western Ethiopia , 2018, PloS one.

[23]  A. Sandford,et al.  Association between tobacco smoking and drug-resistant tuberculosis , 2018, Infection and drug resistance.

[24]  M. Atif,et al.  Analysis of tuberculosis treatment outcomes among pulmonary tuberculosis patients in Bahawalpur, Pakistan , 2018, BMC Research Notes.

[25]  P. Dewan,et al.  Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007–2011): Evidence leading to policy enhancement , 2018, PloS one.

[26]  A. Melese,et al.  Factors associated with poor treatment outcome of tuberculosis in Debre Tabor, northwest Ethiopia , 2018, BMC Research Notes.

[27]  Z. Butt,et al.  Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[28]  Z. Jia,et al.  Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  Zainab,et al.  Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients , 2016, American journal of therapeutics.

[30]  A. Kritski,et al.  Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis , 2017, BMC Infectious Diseases.

[31]  S. M. Zaidi,et al.  Emergence of fluoroquinolone resistance among drug resistant tuberculosis patients at a tertiary care facility in Karachi, Pakistan , 2017, BMC Research Notes.

[32]  A. Nafees,et al.  Pulmonary Tuberculosis Is Associated With Biomass Fuel Use Among Rural Women in Pakistan: An Age- and Residence-Matched Case-Control Study , 2017, Asia-Pacific journal of public health.

[33]  Natasha Rybak,et al.  Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine , 2017, BMC Infectious Diseases.

[34]  T. Xiao,et al.  Reasons for Non-Enrollment in Treatment among Multi-Drug Resistant Tuberculosis Patients in Hunan Province, China , 2017, PloS one.

[35]  Sadia Majeed,et al.  Prevalence and drug resistance pattern of MDR TB in retreatment cases of Punjab, Pakistan. , 2016, JPMA. The Journal of the Pakistan Medical Association.

[36]  K. Mehta,et al.  Treatment outcome among cases of multidrug-resistant tuberculosis (MDR TB) in Western India: A prospective study. , 2016, Journal of infection and public health.

[37]  D. Sloan,et al.  Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings , 2016, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[38]  I. Ullah,et al.  Pattern of Drug Resistance and Risk Factors Associated with Development of Drug Resistant Mycobacterium tuberculosis in Pakistan , 2016, PloS one.

[39]  A. Javaid,et al.  Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[40]  M. Bonnet,et al.  Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia. , 2015, The Journal of infectious diseases.

[41]  W. Ssengooba,et al.  Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert®MTB/RIF in Kampala, Uganda: a retrospective study , 2014, BMC Infectious Diseases.

[42]  Amita Gupta,et al.  Gender-Related Barriers and Delays in Accessing Tuberculosis Diagnostic and Treatment Services: A Systematic Review of Qualitative Studies , 2014, Tuberculosis research and treatment.

[43]  T. Holtz,et al.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes , 2012, European Respiratory Journal.

[44]  M. Petticrew,et al.  The social determinants of tuberculosis: from evidence to action. , 2011, American journal of public health.

[45]  R. Chaisson,et al.  Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence , 2011, PloS one.